Current Opinion in Obstetrics and Gynecology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Circulating tumor cells in metastatic breast cancer: clinical relevance and biological potential
Purpose of review The possibility of tumor dissemination through the blood system has been known for years. Circulating tumor cells (CTCs) are detectable in the peripheral blood of patients with early as well as metastatic breast cancer. The prognostic relevance of this biomarker has already been described. By the use of repeated blood sampling along the course of disease, CTCs can be monitored in terms of a regular ‘liquid biopsy’. This review aims to summarize recent research findings and actual ongoing clinical studies to demonstrate the actual and future relevance of CTCs in daily clinical routine. Recent findin...
Source: Current Opinion in Obstetrics and Gynecology - December 22, 2018 Category: OBGYN Tags: BREAST CANCER: Edited by Peter A. Fasching Source Type: research

Translational highlights in breast cancer research and treatment: recent developments with clinical impact
Purpose of review Over the last decades the time which is needed to translate a preclinical finding or idea in the clinic has reduced continuously. Especially but not only for breast cancer the number of tested drugs and targeted pathways have increased immensely. In addition, the introduction of immune-oncological treatments has further advanced the possibilities for future treatments. This review focuses on recent developments in the prevention and treatment of breast cancer including results from major clinical trials and recent conferences. Recent findings Many pathways involved in the progression or treatment of ...
Source: Current Opinion in Obstetrics and Gynecology - December 22, 2018 Category: OBGYN Tags: BREAST CANCER: Edited by Peter A. Fasching Source Type: research

Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances
Purpose of review Cyclin-dependent kinases (CDK) are key regulatory enzymes that control cell cycle and cell division. In the recent years, new therapeutic options selectively targeting CDK 4 and 6 have shown promising clinical activity in several solid tumors. Since 2015, three CDK 4/6 inhibitors have been approved for treatment of hormone receptor-positive HER2-negative metastatic breast cancer: palbociclib, ribociclib and abemaciclib. These drugs share a common mechanism of action and have been evaluated in studies with a similar design. The following review gives a clinical overview of the CDK 4/6 inhibitors in breas...
Source: Current Opinion in Obstetrics and Gynecology - December 22, 2018 Category: OBGYN Tags: BREAST CANCER: Edited by Peter A. Fasching Source Type: research

Single-cell sequencing in ovarian cancer: a new frontier in precision medicine
This article discusses the advances, applications and challenges of using single-cell RNA sequencing data in guiding treatment decisions for ovarian cancer. Recent findings Genetic heterogeneity is a hallmark of ovarian cancer biology and underlies treatment resistance. Defining the different cell types present within a single ovarian cancer is difficult, but could ultimately lead to improvements in diagnosis and treatment. Next-generation sequencing technologies have rapidly increased our understanding of the molecular landscape of epithelial ovarian cancers, but the majority of these studies are conducted on bulk samp...
Source: Current Opinion in Obstetrics and Gynecology - December 22, 2018 Category: OBGYN Tags: GYNECOLOGIC CANCER: Edited by Gottfried E. Konecny Source Type: research

Cell-based immunotherapy in gynecologic malignancies
Purpose of review To provide an update on cell-based immunotherapies in solid tumors particularly in gynecological cancers. Recent findings Improvements have been made in engineering T cells to overcome the immunosuppressive environment in ovarian cancer. Significant efforts are underway to create ‘off the shelf’ cell therapies which leverage natural killer (NK) cells and would not rely on engineering a patient's T cells. Summary Efforts to target solid tumors using cell-based therapies are expanding into cell types other than T cells (NK cells and macrophages) which may have a lower risk of significant side ef...
Source: Current Opinion in Obstetrics and Gynecology - December 22, 2018 Category: OBGYN Tags: GYNECOLOGIC CANCER: Edited by Gottfried E. Konecny Source Type: research